Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine and Oxybutynin for OSA in Children with Down Syndrome
NCT04115878Phase 2Completed
- Sponsor
- University of Arizona
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine and oxybutynin in obstructive sleep apnea (OSA) (2 arms), sponsored by University of Arizona. Primary endpoint: Obstructive Apnea-hypopnea Index at 4 weeks. Started Oct 2020; status: completed.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04115878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115878.